Printer Friendly

Biogen Idec (NASDAQ: BIIB) - Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis -- 30/7/2019.

--Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (Gl) Tolerability on EVOLVE-MS-2 Study's Primary Endpoint Assessing Self-Reported Gl Events--

--Discontinuations Due to Gl Events were Less than 1% for Diroximel Fumarate--

DUBLIN, Ireland and CAMBRIDGE, Mass., July 30, 2019 (GLOBE NEWSWIRE)--Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced positive topline results from EVOLVE-MS-2, a large, randomized, double-blind, five-week, Phase 3 study of diroximel fumarate, an investigational, novel oral fumarate with a distinct chemical structure, for relapsing-remitting multiple sclerosis (RRMS), compared to TECFIDERA[R] (dimethyl fumarate). Diroximel fumarate was statistically superior to dimethyl fumarate on the study's pre-specified primary endpoint, with patients treated with diroximel fumarate self-reporting significantly fewer days of key gastrointestinal (Gl) symptoms with intensity scores [greater than or equal to]2 on the Individual Gastrointestinal Symptom and Impact Scale (IGISIS), as compared to dimethyl fumarate (p=0.0003).

The most common adverse events (AEs) reported in the study for both treatment groups were flushing, diarrhea and nausea (32.8%, 15.4% and 14.6% for diroximel fumarate; 40.6%, 22.3% and 20.7% for dimethyl fumarate). The overall proportion of patients with AEs leading to study discontinuation were 1.6% for diroximel fumarate and 6.0% for dimethyl fumarate. Of those, the proportion of patients who discontinued due to Gl adverse events during the five-week treatment period were 0.8% for diroximel fumarate and 4.8% for dimethyl fumarate. Further analysis of the data from the EVOLVE-MS-2 study is ongoing and will be presented at a future scientific forum.

"As part of our leadership in multiple sclerosis, Biogen has long understood that the disease differs from person to person, as well as throughout the course of the disease. We are committed to offering a range of options to patients to meet their needs," said Michael Ehlers, executive vice president, research & development at Biogen. "These data build on the foundation we have created with TECFIDERA, the most prescribed oral MS therapy worldwide, and further demonstrate the potential of diroximel fumarate as a novel oral fumarate within our MS portfolio."

"Diroximel fumarate demonstrated statistically superior Gl tolerability compared to dimethyl fumarate on the EVOLVE-MS-2 study's primary endpoint, as well as a low discontinuation rate of less than 1% due to Gl adverse events. These results reinforce the safety and tolerability profile diroximel fumarate has consistently demonstrated across the EVOLVE-MS development program, underscoring the potential importance of diroximel fumarate for the treatment of people living with relapsing-remitting MS. We look forward to the FDA's completion of its review of the diroximel fumarate NDA in the fourth quarter," said Craig Hopkinson, M.D., chief medical officer and senior vice president of medicines development and medical affairs at Alkermes.

EVOLVE-MS-2 was a Phase 3, multicenter, double-blind, active-controlled, five-week study designed to evaluate the Gl tolerability, including duration and severity, of diroximel fumarate 462 mg twice daily compared to dimethyl fumarate 240 mg twice daily in 506 patients with RRMS. The study's primary endpoint assessed the number of days patients reported Gl symptoms with a symptom intensity score [greater than or equal to]2 on the IGISIS rating scale spanning 0 (not at all) through 10 (extreme). The IGISIS was completed twice daily and evaluated the intensity of key Gl symptoms, including nausea, vomiting, upper and lower abdominal pain, and diarrhea.

"With a chronic disease like MS, interrupting or stopping treatment due to Gl side effects can often provoke the return of disease activity. Physicians and patients should work together to choose a medication that provides the right balance of efficacy, safety and tolerability to help manage patients' MS and meet their treatment goals," said Robert Naismith, M.D., professor of neurology, Washington University School of Medicine in St. Louis. "These topline results suggest that diroximel fumarate offers a differentiated Gl tolerability profile and may represent an important new option for people living with relapsing MS."

The EVOLVE-MS-2 study is part of the EVOLVE-MS diroximel fumarate clinical development program, which is being conducted as part of a worldwide development and commercialization agreement between Alkermes and Biogen. Diroximel fumarate is currently under review with the U.S. Food and Drug Administration (FDA) with a PDUFA (Prescription Drug User Fee Act) target action date in the fourth quarter of 2019. Biogen intends to market diroximel fumarate under the conditionally approved brand name VUMERITY[TM].

http://investors.biogen.com/news-releases/news-release-details/diroximel-fumarate-demonstrated-significantly-improved
COPYRIGHT 2019 Acquisdata Pty Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Media Releases
Publication:US Biotech
Article Type:Clinical report
Date:Aug 8, 2019
Words:728
Previous Article:Amgen (NASDAQ: AMGN) - Amgen Reports Second Quarter 2019 Financial Results -- 30/7/2019.
Next Article:Alexion Pharmaceuticals (NASDAQ: ALXN).
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |